The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 30 of the 78 sources its claims cite were checked for support.
Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants
Open accessAbstract
Mitochondrial dysfunction in pathogenic fungi or model yeast causes altered susceptibilities to antifungal drugs. Here we have characterized the role of mitochondrial complex I (CI) of Candida albicans in antifungal susceptibility. Inhibitors of CI to CV, except for CII, increased the susceptibility of both patient and lab isolates, even those with a resistance phenotype. In addition, in a C. albicans library of 12 CI null mutants, 10 displayed hypersusceptibility to fluconazole and were severely growth inhibited on glycerol, implying a role for each gene in cell respiration. We chose two other hypersusceptible null mutants of C. albicans, the goa1Δ and ndh51Δ mutants, for transcriptional profiling by RNA-Seq. Goa1p is required for CI activity, while Ndh51p is a CI subunit. RNA-Seq revealed that both the ndh51Δ mutant and especially the goa1Δ mutant had significant downregulation of transporter genes, including CDR1 and CDR2, which encode efflux proteins. In the goa1Δ mutant, we noted the downregulation of genes required for the biogenesis and replication of peroxisomes, as well as metabolic pathways assigned to peroxisomes such as β-oxidation of fatty acids, glyoxylate bypass, and acetyl coenzyme A (acetyl-CoA) transferases that are known to shuttle acetyl-CoA between peroxisomes and mitochondria. The transcriptome profile of the ndh51Δ mutant did not include downregulation of peroxisome genes but had, instead, extensive downregulation of the ergosterol synthesis gene family. Our data establish that cell energy is required for azole susceptibility and that downregulation of efflux genes may be an outcome of that dysfunction. However, there are mutant-specific changes that may also increase the susceptibility of both of these C. albicans mutants to azoles.
Overview
CoChat Summary
TL;DR
Inhibiting or deleting mitochondrial electron transport chain complex I (CI) in *Candida albicans* increases susceptibility to azoles, and RNA-Seq of the hypersusceptible *goa1Δ* and *ndh51Δ* mutants shows downregulation of efflux transporter genes (*CDR1*, *CDR2*) plus mutant-specific changes. The authors conclude that cell energy is required for azole susceptibility and that efflux-gene downregulation may be an outcome of that dysfunction.
Key findings
- Inhibitors of CI to CV (except the CII inhibitor TTFA, which had only a minor 1-dilution effect) increased fluconazole susceptibility of *C. albicans* SC5314; the CI inhibitor C12E8 raised susceptibility to a fluconazole MIC₈₀ of 0.063 μg/ml. In 42 lab and patient isolates, 14 were hypersusceptible with PdA or C12E8 plus 0.2 μg/ml fluconazole versus 4 with 0.2 μg/ml fluconazole alone, and hypersusceptibility increased at 4 and 32 μg/ml fluconazole, including among CDR- and MDR-overexpressing resistant isolates.
- Of 12 putative CI null mutants, 10 were hypersusceptible to 16 μg/ml fluconazole and 9 of those 10 failed to grow on glycerol (YPG), linking respiratory deficiency to fluconazole hypersensitivity; two mutants (orf19.3611, orf19.3290) had wild-type susceptibility and grew on YPG.
- The *goa1Δ* mutant was hypersensitive to fluconazole (16 μg/ml), itraconazole (0.4 μg/ml), ketoconazole (0.8 μg/ml), and miconazole (1.0 μg/ml) but equal to wild type for 5-flucytosine, amphotericin B, and micafungin; *ndh51Δ* was also hypersensitive to fluconazole (16 μg/ml). Neither *goa1Δ*, *ndh51Δ*, *tac1Δ*, nor *cdr1/2Δ* adapted to 128 μg/ml fluconazole by 4–6 days, whereas wild type and CDR1/CDR2- and MDR1-overexpressing strains did.
- RNA-Seq showed 388 genes downregulated ≥4-fold in *goa1Δ*, with top GO categories being transmembrane transporter activity (13%), amino acid metabolism (9%), carbohydrate metabolism (7%), mitochondria (4%), and peroxisomal β-oxidation (3%); both mutants downregulated transporter genes including *CDR1* and *CDR2*. *goa1Δ* additionally downregulated peroxisome biogenesis/replication and peroxisomal metabolic pathways, whereas *ndh51Δ* instead showed extensive downregulation of the ergosterol synthesis gene family.
Methods
- Susceptibility testing by CLSI M-27A broth microdilution in 96-well plates (OD₅₉₅ after 24 h at 30°C, ≥3 replicates) with ETC complex inhibitors alone or combined with fluconazole, plus drop-plate assays on YPD/YPG agar and fluconazole adaptation assays at 128 μg/ml.
- A library of 12 *C. albicans* homozygous CI deletion mutants (from Noble and Johnson) was screened for fluconazole susceptibility and growth on glycerol; the *goa1Δ* and *ndh51Δ* null mutants and their reconstituted strains were studied in detail.
- RNA-Seq (Illumina HiSeq2000, paired-end 90–100 nt; 11,279,512 wild-type, 10,906,588 *goa1Δ*, and 10,630,834 *ndh51Δ* reads) mapped to SC5314 with TopHat 1.3.3 and analyzed with Cufflinks 1.2.1/Cuffdiff, with selected genes validated by real-time PCR; rhodamine 6G efflux measured energy-dependent efflux.
Limitations
- Not stated in the paper — the provided text is truncated before any discussion/limitations section, so the authors' own stated limitations cannot be reported.
- Evident from the text: transcriptome profiling covers only two mutants (*goa1Δ* and *ndh51Δ*) compared against a single wild-type strain, and the RNA-Seq analysis is a static snapshot rather than a time course; the paper also relies on a single library of 12 putative CI mutants for the deletion screen.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
24 Valid · 3 Not valid · 3 Not checked · 48 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mitochondrial dysfunction in pathogenic fungi or model yeast causes altered susceptibilities to antifungal drugs.”
What the sources say
- Not checked — no full text of the sourcecites [7] source
- Not checked — no full text of the sourcecites [8] source
- Supportedcites [9] source
The Introduction (page unavailable) links loss of mitochondrial function in the pathogenic fungus Candida glabrata to acquired azole resistance. The Abstract (page unavailable) reports that a mitochondrial-deficient isolate was resistant to fluconazole while its related parent isolate was susceptible. Azoles are antifungal drugs, so this supports the claim through the pathogenic-fungus example. (LLM, conf=0.90)
- Supportedcites [10] source
The Abstract (p. 1600) reports that C. glabrata mutants defective in mitochondrial assembly and organization had very high fluconazole resistance. Fluconazole is an antifungal drug, so this supports the claim that mitochondrial dysfunction can alter antifungal susceptibility in a pathogenic yeast. (LLM, conf=0.91)
- Partly supportedcites [11] sourceExperimental — accuracy not yet measured
The Discussion (page not available) shows that loss of mitochondrial function produced azole resistance in C. glabrata, a pathogenic yeast. It reports only preliminary, unpublished evidence of a similar relationship in the model yeast S. cerevisiae and says azole resistance from mitochondrial loss had not been reported in other human-pathogenic yeasts. The claim states the effect more broadly and definitively than this evidence supports. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [12] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Strains with genes deleted accumulate ROS, undergo apoptosis, and are avirulent.”
What the sources say
- Not checked — no full text of the sourcecites [18] source
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results (Fig. 5; page unavailable) report increased ROS in the GOA1-deletion strain GOA31. The paper mentions an NDH51-deletion strain in connection with a filamentation defect, but does not report that it accumulates ROS. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [20] source
- Not checked — no full text of the sourcecites [21] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Goa1p is required for optimum electron transport chain (ETC) complex I (CI) activity.”
- Also stated in: § Materials and Methods · plain
“Goa1p is required for ETC CI activity, while Ndh51p is a subunit of ETC CI.”
What the sources say
- Not checked — no full text of the sourcecites [18] source
- Supportedcites [19] source
The Discussion states that Goa1p is required for mitochondrial functions, especially complex I activity. The Results show that deleting GOA1 reduced complex I specific activity by about 80% relative to wild-type C. albicans cells, while the gene-reconstituted strain had near-wild-type activity. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [20] source
- Not checked — no full text of the sourcecites [21] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Materials and Methods · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Recently, knockout strains of C. albicans have been constructed that lack either GOA1 or NDH51 (18–21).”
What the sources say
- Not checked — no full text of the sourcecites [18] source
- Supportedcites [19] source
The paper describes a C. albicans GOA1 deletion strain, GOA31, and states that a C. albicans NDH51 deletion mutant had been studied. These passages support the claim that knockout strains lacking either gene have been constructed; they do not imply that this paper constructed both strains. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [20] source
- Not checked — no full text of the sourcecites [21] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Strains with genes deleted accumulate ROS, undergo apoptosis, and are avirulent.”
What the sources say
- Not checked — no full text of the sourcecites [18] source
- Partly supportedcites [19] sourceExperimental — accuracy not yet measured
The Results section reports increased apoptosis in the GOA1-deletion strain GOA31, supported by caspase and TUNEL assays; the paper also reports increased ROS and notes prior evidence of avirulence for this strain. Its discussion of NDH51 deletion mentions a filamentation defect, not apoptosis, so the claim is unsupported for NDH51. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [20] source
- Not checked — no full text of the sourcecites [21] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
46 more claims · 8 with their cited sources checked
Create a free account to see all 78 claims and every source verdict.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In C. albicans , mitochondria are power houses which are needed for many cellular processes, such as drug susceptibility, cell wall integrity, phospholipid homeostasis, and virulence.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Deficiency of CI will result in cellular ROS accumulation, apoptosis, and increased susceptibility to fluconazole in Candida albicans (14–16).”
From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, the inhibitors of mitochondrial complex I (CI) or complex V (CV) can always improve the outcome of fl uconazole treatment in patients or the lab isolates.”
From The synthesis, regulation, and functions of sterols in Candida albicans: Well-known but still lots to learn (2016) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial CI is the largest and most complicated enzyme complex in OXPHOS and is responsible for pumping electrons into the ETC and generating intracellular ROS.”
From Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review (2023) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The latter was confirmed by the use of ETC inhibitors (including antimycin A), resulting in increased sensitivity to fluconazole.”
From Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms (2016) · cites this paper as [40]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“The CI inhibitors C128E and PdA were assayed in combination with 0.2, 4, or 32 μg/ml of fluconazole.”
“fluconazole (0, 2, 4, or 32 μg/ml)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“At a fluconazole concentration of 128 μg/ml in YPD, adaptation occurred by 4 to 6 days”
“plated on SD medium containing 128 μg/ml of fluconazole”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“10 displayed hypersusceptibility to fluconazole and were severely growth inhibited on glycerol”
“Nine of the 10 hypersusceptible CI mutants did not grow on YPG medium”
Citations
Cites
Pao, S. S., Paulsen, I. T., & Saier, M. H. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.1.1-34.1998 · Cited by 2,297
The glyoxylate cycle is required for fungal virulence
Lorenz, M. C., & Fink, G. R. (2001) · Nature · doi:10.1038/35083594 · Cited by 745
Transcriptional Response of Candida albicans upon Internalization by Macrophages
Lorenz, M. C., Bender, J. A., & Fink, G. R. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.5.1076-1087.2004 · Cited by 712
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 1×
“When large numbers of cells are plated on a high concentration of fluconazole, a rapid adaptation to decreased susceptibility has been observed in wild-type cells (25).”
BackgroundNoble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Genetic control of Candida albicans biofilm development
Finkel, J. S., & Mitchell, A. P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2475 · Cited by 612
Cargo-Selected Transport from the Mitochondria to Peroxisomes Is Mediated by Vesicular Carriers
Neuspiel, M., Schauss, A. C., Braschi, E., Zunino, R., Rippstein, P., Rachubinski, R. A., Andrade-Navarro, M. A., & McBride, H. M. (2008) · Current Biology · doi:10.1016/j.cub.2007.12.038 · Cited by 589
Mitochondria as a Pharmacological Target
Szewczyk, A., & Wojtczak, L. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.1.101 · Cited by 538
The mitochondrial contact site complex, a determinant of mitochondrial architecture
Harner, M., Körner, C., Walther, D., Mokranjac, D., Kaesmacher, J., Welsch, U., Griffith, J., Mann, M., Reggiori, F., & Neupert, W. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.379 · Cited by 477
Coste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Cited by
Mechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
“However, pharmacological inhibition of mitochondrial complexes involved in respiration and energy production results in higher susceptibility to azoles in this species (Sun et al. 2013).”
BackgroundMesa-Arango, A. C., Trevijano-Contador, N., Román, E., Sánchez-Fresneda, R., Casas, C., Herrero, E., Argüelles, J. C., Pla, J., Cuenca-Estrella, M., & Zaragoza, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03570-14 · Cited by 232
“the optimal amount that inhibited cell growth (58, 59).”
BackgroundMethodFreires, I. D. A., Murata, R. M., Furletti, V. F., Sartoratto, A., Alencar, S. M. D., Figueira, G. M., de Oliveira Rodrigues, J. A., Duarte, M. C. T., & Rosalen, P. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099086 · Cited by 187
“In addition to the primary mechanisms of action of antifungals (b-Glucans biosynthesis blocking and disturbance in ergosterol synthesis or function) [42], some agents can also have alternative effects on other targets, for instance on mitochondrial activity, which plays a role in generation and regulation of Reactive…”
BackgroundLv, Q.-Z., Yan, L., & Jiang, Y.-Y. (2016) · Virulence · doi:10.1080/21505594.2016.1188236 · Cited by 133
Thomas, E., Roman, E., Claypool, S., Manzoor, N., Pla, J., & Panwar, S. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00889-13 · Cited by 105
“albicans, deletion of mitochondria localized GOA1 renders cells highly susceptible to azoles and cell wall damaging agents (12, 13).”
BackgroundResultInfluential
Metadata
- Authors
- Sun, N., Fonzi, W., Chen, H., She, X., Zhang, L., Zhang, L., & Calderone, R.
- Affiliations
- Georgetown University Medical Center (US)
- Georgetown University (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Chinese Academy of Sciences (CN)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-01
- Volume
- 57
- Issue
- 1
- Pages
- 532-542
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3535965
- OpenAlex
- W2096468377
- Semantic Scholar
- 196f80f4c32314f2d9a8fc2f431b310373ef7eb7
- Cited by
- 94
- References
- 46
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 2 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 4 · 2017: 12 · 2016: 6 · 2015: 8 · 2014: 12 · 2013: 4
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Georgetown University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- Candida albicans, mitochondrial complex I, azole susceptibility, fluconazole, antifungal resistance, mitochondrial dysfunction, CDR1, CDR2, peroxisome biogenesis, ergosterol biosynthesis, cellular respiration, gene expression profiling
- MeSH terms
- Antifungal Agents, Candida albicans, Electron Transport, Ergosterol, Fungal Proteins, Microbial Sensitivity Tests, Mitochondria, Mutation, Fluconazole, Gene Expression Regulation, Fungal, ATP-Binding Cassette Transporters, Peroxisomes, Gene Expression Profiling, Drug Resistance, Fungal, Electron Transport Complex I, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants. https://app.cochat.ai/papers/10.1128/aac.01520-12
- The paper
- Sun, N., Fonzi, W., Chen, H., She, X., Zhang, L., Zhang, L., & Calderone, R. (2013). Azole Susceptibility and Transcriptome Profiling in Candida albicans Mitochondrial Electron Transport Chain Complex I Mutants. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01520-12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.